Read how inflammation impacts the immune system and how diet and nutritional supplements can potentially help immune system functions.

Learn about the properties — including a biomarker for efficacy, known and unknown mechanisms of action and more — of minoxidil, the only FDA approved topical active pharmaceutical ingredient (API) for alopecia in men and women.

Polycystic ovary syndrome (PCOS) is the most prevalent hormonal disorder affecting women of reproductive age across the globe and the CDC estimates PCOS may be one of the most common causes of infertility. Learn how to help patients with PCOS.

Genitourinary syndrome of menopause (GSM), also known as vulvovaginal atrophy, is common among menopausal women. Learn more about GSM, relevant hormones and the importance of choosing the right base for compounding preparations.

Wellness Works Manager Stephanie Allen reviews nutritional supplements that may help women thrive.

Tricia Heitman of PCCA's Clinical Services Team discusses compounded treatment options for women suffering from atropic vaginitis, vluvar lichen sclerosis, desquamative inflammatory vaginitis, vaginismus, high-tone pelvic floor dysfunction and vulvodynia.

Maria Carvalho, Manager of PCCA Science, provides an in-depth look at the science behind Ellage, the first ever anhydrous compounding base developed specifically for vaginal delivery of medications.

With the debut of Ellage at International Seminar 2020, PCCA has introduced a revolutionary anhydrous vaginal base. Here are just a few of the exciting reasons why Ellage should be your pharmacy's go-to base when it comes to vaginal applications.

Sara Hover of PCCA's Clinical Services discusses medical treatment and management options for pharmacists helping patients whose health is challenged by polycystic ovary syndrome (PCOS).

In the first part of this article, Pamela, Nat, and Sara shined a light on new health risk information compounders should consider when providing bioidentical hormone replacement therapy. In this second part of the article, they dive deeper into the BHRT conversation, discussing compounded topical estrogen as an option.